Adaptimmune Therapeutics PLC - ADR (ADAP) stock is lower by -8.15% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives ADAP stock a score of 66 out of a possible 100.
That rank is mainly influenced by a fundamental score of 98. In addition to the average rating from Wall Street analysts, ADAP stock has a mean target price of $10.33. This means analysts expect the stock to rise 177.77% over the next 12 months. ADAP's rank also includes a long-term technical score of 54. The short-term technical score for ADAP is 45.
ADAP has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on ADAP!
Adaptimmune Therapeutics PLC - ADR (ADAP) stock is up 0.68% while the S&P 500 is higher by 0.31% as of 10:58 AM on Friday, Dec 10. ADAP is higher by $0.02 from the previous closing price of $3.69 on volume of 180,556 shares. Over the past year the S&P 500 is up 27.64% while ADAP is lower by -8.15%. ADAP lost -$1.00 per share in the over the last 12 months.
Click Here to get the full Stock Report for Adaptimmune Therapeutics PLC - ADR stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
